University of California Davis

Top questions in iPS cell research

Every once in a while CIRM grantee Paul Knoepfler at UC Davis posts an update on his blog about what he considers to be the big ticket question in research using reprogrammed adult cells, known as iPS cells. This time, he's posted five questions for the upcoming year.

A welcome voice in stem cell communication - a new podcast launches

CIRM grantee Paul Knoepfler at UC Davis has been blogging about stem cell science for a while now. He recently expanded his outreach to include a regular podcast. It's worth checking out. He's listing the most recent podcast at the top of his main blog page: .

Blood from stem cells?

Blood has been among the most sought after and hardest to achieve tissue that CIRM grantees are attempting to derive from embryonic stem cells. It's an obvious target. The medical system needs a constant influx of blood, which comes entirely from volunteer donors. Creating that blood in an unlimited supply from human embryonic stem cells would significantly ease concerns about blood shortages at hospitals.

CIRM a leader in iPS cell publications

Yesterday, stem cell blogger and newly tenured CIRM grantee at UC Davis Paul Knoepfler had an interesting blog entry on iPS cell publications.

CIRM grantees begin testing stem cells to prevent amputations

CIRM grantees at UC Davis have begun a trial that, if successful, could help prevent some amputations caused by blockages in the blood vessels.

Stem cell research like picking stocks? We don't think so.

A story by Nick Wade in Monday's New York Times rubbed some scientists the wrong way - and I must admit the piece was not too popular around CIRM headquarters.

Wade equated research funding with picking stocks. His idea is that a broad portfolio is bound to include some winners (he attributes this approach to the NIH and NSF) whereas attempts to only buy the big winners can produce a risky portfolio (an approach he attributes to CIRM).

Federal stem cell legislation unlikely in lame duck session

Science had a story this morning about what yesterday's elections mean for stem cell funding. In it they suggest it's unlikely that the lame duck congressional session will bring legislation to expressly legalize federal funding for human embryonic stem cell research, writing:

Growing space for California stem cell research

On left and right, Berkeley Stem Cell Center co-directors
David Schaffer and Randy Shekman, and center,


Subscribe to RSS - University of California Davis

© 2013 California Institute for Regenerative Medicine